匹多莫德联合重组人干扰素α1b及更昔洛韦治疗EB病毒相关性传染性单核细胞增多症患儿的效果

Effect of Pidotimod combined with recombinant human interferonα1b and Ganciclovir in the treatment of children with EB virus associated infectious mononucleosis

目的探讨匹多莫德联合重组人干扰素α1b及更昔洛韦治疗EB病毒(EBV)相关性传染性单核细胞增多症患儿的效果。方法选择安徽省阜阳市妇女儿童医院儿科2018年1月至2021年3月接诊的80例EBV相关性传染性单核细胞增多症患儿为研究对象。依据随机数字表法分为观察组和对照组,每组40例。对照组给予干扰素α1b及更昔洛韦治疗,观察组在对照组的基础上联合匹多莫德治疗,两组均连续治疗10 d。比较两组临床症状改善情况,CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+),肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、白细胞介素-6(IL-6)、肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LDH)、天门冬氨酸氨基转移酶(AST)水平,记录治疗期间不良反应发生情况。结果观察组咽痛消失时间、退热时间、扁桃体和淋巴结肥大缓解时间短于对照组,差异有统计学意义(P<0.05)。治疗后,两组CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)高于治疗前,且观察组高于对照组,差异有统计学意义(P<0.05)。治疗后,两组TNF-α、CRP、IL-6水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组CK、CK-MB、LDH、AST水平低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗期间,两组患儿均未发生明显的不良反应。结论匹多莫德联合重组人干扰素α1b及更昔洛韦治疗EBV相关性传染性单核细胞增多症患儿效果明显,值得推广应用。

Objective To investigate the effect of Pidotimod combined with recombinant human interferonα1b and Ganciclovir in the treatment of children with Epstein-Barr virus(EBV)associated infectious mononucleosis.Methods A total of 80 children with EBV associated infectious mononucleosis admitted to Department of Pediatrics,Fuyang Women and Children’s Hospital,Anhui Province from January 2018 to March 2021 were selected,and they were divided into observation group and control group by random number table method,with 40 cases in each group.Control group was treated with recombinant human interferonα1b and Ganciclovir,and observation group was treated with Pidotimod on the basis of control group,two groups were treated for ten days.Clinical symptoms improved conditions,CD4^(+),CD8^(+),CD4^(+)/CD8^(+),tumor necrosis factor-α(TNF-α),C-reactive protein(CRP),interleukin-6(IL-6),creatine kinase(CK),creatine kinase MB(CK-MB),lactate dehydrogenase(LDH),and aspartate aminotransferase(AST)levels were compared,the occurrence of adverse reactions during treatment were recorded.Results The disappearance time of pharyngeal pain,antipyretic time,and relief time of tonsil and lymph node enlargement in observation group were shorter than those in control group,and the differences were statistically significant(P<0.05).After treatment,CD4^(+),CD8^(+),and CD4^(+)/CD8^(+)in both groups were higher than those before treatment,and observation group was higher than control group,and the differences were statistically significant(P<0.05).After treatment,the levels of TNF-α,CRP,and IL-6 in two groups were lower than those before treatment,and observation group was lower than control group,and the differences were statistically significant(P<0.05).After treatment,the levels of CK,CK-MB,LDH,and AST in two groups were lower than those before treatment,and observation group was lower than control group,and the differences were statistically significant(P<0.05).During the treatment,no obvious adverse reactions occurred in two groups.Conclusion Pidomord combined with recombinant human interferonα1b and Ganciclovir in the treatment of children with EBV associated infectious mononucleosis have obvious effect,it’s worthy of promotion and application.